america
new driver emerg
anoth solid robust gener support
continu upsid share
sharehold reward recent event
color fundament focu call qsr
latest solid tumor readout reaffirm focu heme/onc
dalca achiev steadi state factor express day
margin expans focu ahead
review busi hum ad focu
follow-up look
analyst certif import disclosur see
restructur effort least quarter ahead
close solid progress ceo search continu
end year solid note
stock pricing-in takeout enough
target posit ebitda ride margin improv
nice healthi anr growth maintain outperform
in-lin quarter management remain optimist
merger approv minor price renegoti like
egain report result build consist
execut look back track invoic
chang go creat nois maintain outperform
need repeat
cpst choppi result off-set strong book
tougher setup difficult identifi upsid near-term
still search caffein boost share reiter perform
mix variat soften margin ep
io result disappoint remain sidelin
revis estim suspend busi activ due
coronaviru outbreak
black dark room anymor
new driver emerg
lift price target reiter invest rate
outperform share note assum construct nearer-term stanc
larg upon view market yet appreci fulli signific underli improv within
compani develop omni-channel busi model share ralli track all-tim high
look next sever quarter increasingli opinion improv multipl least
hold still solid strengthen earn growth algorithm compani underpin continu grind
higher share
thorough analysi forc highlight qsr superior risk/reward follow pullback last six month
believ valuat sit unwarr heavi discount peer importantli work highlight case
downsid street ebitda estim along qsr diminut china exposur better growth showcas
limit downsid risk share upsid th comp stabil investor expect result
fade lower headlin ebitda slightli consensu maintain outperform price target
anoth solid robust gener support continu upsid share
report ep ahead oper beat ccm cft result
expect lift favor tax rate highlight revenu growth mark consecut quarter
y/i top-lin expans ebit growth record earn y/i given solid perform also finish
record convers anticip continu ramp importantli ccm
account run rate profit remain well posit enter early-stag providien integr
track self-help lever restrict downside/leverag futur upsid smaller cft cbf ad signific dri
powder believ remain posit outsiz earnings/cash flow growth go forward
recent attend investor meet ceo cfo manag upbeat core storag segment
condit remain solid garner enhanc oper effici successful/complet implement
sap deliv msd rental revenu growth adjust ebitda margin expans nearli doubl
level target delivering/improv upon result storag segment rental rate growth
expect perpetu aid increment contribut strong demand higher-pr ground level offic
furthermor expect ramp compani leverag adjust ebitda growth across lower net
capital-expenditure profil reiter outperform increas target view well-posit sustain
sharehold reward recent event
outperform ytd vs nbi strength recent news includ tecfidera ipr
decis risdiplam updat roch present data part pivot sunfish trial oral
risdiplam part met primari endpoint mean differ vs placebo decreas
slightli part mean improv continu view risdiplam approv seriou
competitor spinraza especi older type patient prefer oral administr see exhibit full report
acknowledg challeng compar sunfish cherish base patient differ prescrib patient
extrapol data potenti limit switch opinion updat model new pt
wireless continu add strong postpaid phone custom growth versu
stabl price drove servic growth vz continu benefit sprint weak cabl almost
monopoli high speed data wireless wirelin sector achiev ebitda growth
respect revenu growth despit declin video revenu advertis expect
sector grow ebitda cabl broadband market share sequenti close
revenu growth subscrib growth cabl grow rang higher arpu
lower spend weak paid tv ott strong cloud growth help infrastructur cdn name
color fundament focu call qsr
latest solid tumor readout reaffirm focu heme/onc
asco-sitc meet thursday forti seven present initi phase result trial explor
combin magrolimab avelumab solid tumor enrich gynecolog cancer amongst efficacy-evalu
ovarian cancer oc patient one unconfirm pr observ second confirm pr observ papillari
adenocarcinoma patient disappoint addit avelumab appreci improv encourag
earli efficaci magrolimab monotherapi pr evalu oc patient believ result provid
justif compani decis priorit develop hematolog malign thesi remain firmli
center magrolimab opportun heme/onc anticip updat result aml md mid-year reiter
dalca achiev steadi state factor express day ada data support phase develop
cbio present posit updat lead hemophilia program includ mean factor ix express level
phase iib dalca studi plateau factor express level day anti-drug antibodi ada
declin factor express level follow achiev peak level view eahad data support move
dalca subq factor ix phase develop potenti end follow ind file us base case
assum cbio seek partner dalca view complet nhp studi cb factor ix gene therapi
import initi partner factor ix franchis separ cbio provid import increment updat
report onpattro global net sale q/q meet consensu earli strength
note uk japan guid onpattro sale y/i midpt launch expand new
geographi diseas awar continu increas givlaari gener strong commun interest launch
leverag now-establish commerci capabl lumasiran approv anticip year attr franchis evolv
onpattro/vutrisiran develop inclisiran royalti stream begin ye view core biotech
margin expans focu ahead
recent respond nomin candid board director activist investor starboard valu
remind starboard disclos hold said initi discuss starboard
compani indic focus improv effici free cash flow note new product
expect come month profit smid-cap med-tech peer trail ebitda margin versu
forecast assum increas focu margin expans effort ahead recent peer multipl expans
assum addit margin expans long-term model though still embed below-p averag margin
point rais price target
review busi hum ad focu
regeneron report sales/earn provid investor updat quarterli revenu
ep beat opco estim respect exhibit top- bottom- line
demonstr strong fourth quarter continu bar typic weak season model
sequenti given focus commerci execut across compani three key product franchis best-in-p
group pipelin progress well remain focus control opex potenti long-term ep leverag
compani guidanc wide anticip updat expect follow final sny/regn antibodi
restructur agreement end updat model stay bullish
follow-up look
ci report ep top opco/street segment result roughli
line estim ep beat aid below-the-lin item issu ep guidanc
line previous impli commentari furthermor manag reiter expect cf
debt-paydown opportun re-invest start follow quarter
rais ep estim overal result strong cigna
continu produc result post-esrx
report strong revenu y/i beat street estim special note
all-tim bill high y/i exceed consensu estimate suggest healthi industri dynam
on-going strong execut improv apac perform y/i vs driven hire
acceler allevi prior region concern emea america remain consist summari view
strong finish indic on-going momentum unfold import view result guidanc
support healthi demand sd-wan custom continu secur fabric adopt new
addit servic estim tweak higher yet reiter outperform rate pt
restructur effort least quarter ahead strand cost in-check subscrib stabil
came ahead plan beat consensu estim revenu vs ep vs
cfo quarterli updat includ restructur process believ ahead plan quarter
complet sep total strand cost track lower origin plan first time
sinc net subscrib qoq arpu y/i market invest ramp
fierc focu shift beyond us intern market applaud new team execut restructur plan
stay ahead unlock oper effici sharehold maintain perform posit bia becom
construct
close solid progress ceo search continu
post beat consensu recur revenu increas annual
recur revenu increas transit ratabl model strategi focus consult busi
higher-margin engag drive increas softwar consumpt depress revenu board continu
search new ceo interim ceo lund continu serv board member new ceo brought
board compani separ role chairman ceo independ director michael gianoni becom
chairman make steadi progress transform recur revenu model refocus
consult busi expand margin maintain perform rate
end year solid note
fleetcor report solid result organ revenu growth vs estim non-cor gift
card miss manag estim fuel card growth remain strong ex-chevron drag grow
reflect otr pressur strateg non-fuel businessescorpor payment toll lodginggrew
organ weak payrol growth tough comp respect provid encourag
outlook ep rang mid-point vs our/street prior estim
organ revenu growth given like sustain high single-digit organ growth busi mix improv signific capit
flexibl and/or repurchas stock remain highli attract us maintain outperform rate rais pt
stock pricing-in takeout enough deal privat compani would dilut
rais target maintain under-perform current valuat assum compani sold
premium marketplac peer current see one realist buyer appear focus effici
profit eat hold posit us gener gb y/i vs
show limit interest us restaur food deliveri could face regulatori scrutini similar situat europ
transact either remain us food deliveri compani would complic would requir dilut
current sharehold via merger oppos sold
target posit ebitda ride margin improv nice healthi anr growth maintain outperform
increas target maintain outperform rate follow better result materi ride margin
upsid possibl faster path posit ebitda management went signific detail improv health ride
impli eat gener year behind expect ebitda profit vs fy trough
eat loss management note success premium comfort busi ride gb
accret margin high-prior market argentina south korea spain grow ride gb faster consolid
increas focu subscript offer rides/eat estim ride ebitda exit
support oour sotp valuat anr
cloud
in-lin quarter management remain optimist merger approv minor price renegoti
primari focu merger sprint manag confid deal get done though price
renegoti seem like given sprint weaken fundament increas debt revenu grew
y/i line est ebitda margin expand y/i aggress estimate due
higher equip cost guidanc ebitda growth next year year higher spend across board
though beaten guidanc seven year ad postpaid phone-onli custom flow share phone
arpu line estim primari one-year concern sprint integr volatil long-
term stock attract
earn recap solid wireless broadband growth weak paid tv
datacent see pressur smb move cloud alway expect insul
fcc draft rule c-band spectrum auction think auction rais
report in-lin quarter guidanc trend remain healthi manag remain optimist merger
though price like renegoti
egain report result build consist execut trend
report dec result consensu estim posit includ go-to-market strategi
appear work good big deal activ partner channel expand relationship avaya good
momentum financi servic vertic healthi cash gener balanc soft emea non-
recur season could caus saa revenu declin sequenti tough optic subscript
busi bottom line repris initi report publish last decemb key take-away
result posit deliv better consist futur quarterli result potenti growth
acceler stori ahead thesi begin take shape reiter outperform
execut look back track invoic chang go creat nois maintain
report good result mostli consensu estim posit go-to-market execut
appear get back track upcom relat confer march pipelin expans
catalyst expect new product enhanc announc could releas pent-up end-market
demand balanc busi chang invoic polici point mostli reduc renew
process friction chang creat nois bill metric year bottom line view increas
invest profil innov growth posit lend support upgrad thesi futur
invest narr sunshin begin take hold maintain outperform
emerg technolog servic
need repeat
year activis argu strategi built around content releas often place
start late chang guard highest level activis blizzard continu
announc cod mobil diablo immort follow overwatch diablo howev still bit
hold pattern guidanc level respect overwatch diablo
year plu away diablo immmort later year new titl announc like even away commerci
earli return look promis see cod mobil cod mw see stock fairli valu
result guidanc came mostli consensu estim driven acquisit revenu trilog
cost save low bar bottom line manag took opportun reset bar domest
graduat program dgp busi inorgan boost financi trilog similar result anticip
next two quarter question whether expect dgp busi lower enough deceler
seen across dgp metric may stabil anytim soon sinc smaller pool potenti fce
competit price pressur capit intens regulatori issu weaken compani posit see potenti
downward revis given uncertainti true like trajectori maintain perform
eu investig radio-frequ chip reuter
coronaviru outbreak impact china smartphon sale nosed digitim
claim win base new market share data extrem
report coronaviru hit graphic card motherboard demand china extrem
sustain growth resourc optim
cpst choppi result off-set strong book
cpst continu refin oper model consist show strong book believ compani
work shorten cycl time leverag nation account familiar product also believ cpst oil
ga custom activ tri avoid flare product cash flow reason improv environment
footprint continu watch compani abil lower direct materi cost overhead reach ebitda
break-even remain sidelin confid abil cpst deliv reach
tougher setup difficult identifi upsid near-term
given system-sal china model set under-perform target double-digit ep algorithm
separ neg trend us pizza hut busi profit also headwind normal model
base analysi initi stab earn growth impli consensu may need revis ep
vs prior print given stock richer valuat upsid share appear reliant posit
earn revis cycl look unlik occur
still search caffein boost share reiter perform
post healthi result issu earn guidanc line oper slightli ep
basi manag believ tool drive low-single-digit compstore dunkin-u despit toughest comparison sinc
lap espresso launch management overal profit outlook includ plan invest new beverag equip
design upgrad product qualiti hot coffe oper slightli lower ep estim align
guidanc maintain perform rate
report adj ep line our/consensu estim modest oper miss aw
segment lift favor below-the-lin item fourth quarter organ sale flat util industri
commerci residenti adj margin slightli lower y/i weaker volum unfavor mix partli off-set product
price given continu soft industri commerci demand manag initi guidanc reflect near-term
conservat diverg expect year organ growth guid ep improv
growth expect -lsd rang vs challeng comp rebound msd territori easier
comp ramp deploy accordingli ep expect back half
mix variat soften margin ep
revenu sot organ line though lower margin expect mix impact
rs sale bit light organ slower demand oem dealership lumpi oem grew msd
combin profit strong includ benefit mitchel software-rel busi growth driver shift
within sot diagnost hand tool weak power tool strong flip trend creat mix
product categori shift normal reflect differ foci quarter quarter trim estim forego
sot om expans bp snap-on credit assum cecl impact on-going
sustain growth resourc optim
share trade intra-day report result consensu estim reflect greater impact
richmond facil fire pocket industri soft emea forklift class truck manag outlook
materi potenti come late look line infrastructur vendor expect believ
degre engag key custom bode well enss futur particip revenu capac come
on-lin next sever quarter new channel opportun emerg transport see setup return
organ growth rais adj ep estim maintain estim price target
sustain growth resourc optim
deliv upsid revenu guidanc street expect grid busi continu perform well note
wind sale declin y/i total compani revenu grew y/i believ develop strong product
portfolio see posit custom respons notabl get visibl next sp project gm sequenti
ramp new grid product yet reach matur cost structur given limit cash burn clear line
sight gener posit ebitda current product offer custom base remain bullish look
improv margin profil revenu ramp maintain outperform rate lower pt
sustain growth resourc optim
io result disappoint remain sidelin
io report disappoint result spend live expect current macro headwind
oil demand due part coronaviru cautiou near-term recoveri spend encourag
compani embark restructur program believ busi need right-siz remain posit
ion technolog portfolio encourag progress marlin offer see potenti ion
aggreg technolog serv off-shor explor remain sidelin compani work
restructur industri find stabl supply/demand balanc
revis estim suspend busi activ due coronaviru outbreak
follow ceo-host call analyst last even revis best estim consid essenti
suspens transport logist activ china current given lock-down across all-siz citi throughout
countri expect persist least and/or like gradual rebound activ thereaft even
date get push model substanti reduc revenu februari march respect safeti
associates/partn manag expens wherev possibl anticip cost control maintain pace
commensur anticip revenu decreas acknowledg limit visibl moder reduc
estim junctur revenue/adjust ebitda/ep reduc y/i
vs respect
black dark room anymor
report adjust ep line estim consensu overal compani deliv
strong quarter provid solid financi outlook surprisingli earn call fill discussion/
question around take-over talk criteria financi return growth initi potenti help
consum marketplac believ inevit import convers sinc investor decid whether
still want could potenti becom intercontinent massiv scalabl network databas
compani howev discuss appear becom distract compani strong fundament core
trade data busi continu gener massiv cash flow sharehold like year come
report dec ep vs estim consensu estim exclud
item includ posit mark ta cost relat transact acquisit cost
compani report adjust ep vs estim oper result larg line therefor view
quarter larg line believ weak share due weaker expect ep guidanc next
quarter part delta driven one-off item current valuat evergreen contract lock
fix fee limit downsid signific upsid potenti acquisit share price appreci manag
reit incent fee
last month publish shorten initi review schedul issu late last night publish final
version januari report contain usual exhibit mr market still wrong disrespect bank bkx
ytd vs bank beat estim report basi fundament basi
gs litig charg rais estim cut rais cut see
exhibit full report date consensu estim also gener went bottom line pretti good
shape exhibit despit hand wring yield curv return also good shape group post
rotc year similar last year roughli line estim exhibit
may biotech summit featur chemistri life process institut chicago il
juli montauk summit emerg life scienc montauk ny
